Lipocalin-2 is associated with radioresistance in oral cancer and lung cancer cells

  • Authors:
    • Masashi Shiiba
    • Kengo Saito
    • Kazuaki Fushimi
    • Takashi Ishigami
    • Keiji Shinozuka
    • Dai Nakashima
    • Yukinao Kouzu
    • Hirofumi Koike
    • Atsushi Kasamatsu
    • Yosuke Sakamoto
    • Katsunori Ogawara
    • Katsuhiro Uzawa
    • Yuichi Takiguchi
    • Hideki Tanzawa
  • View Affiliations

  • Published online on: February 8, 2013     https://doi.org/10.3892/ijo.2013.1815
  • Pages: 1197-1204
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to identify a target molecule that could predict the efficacy of radiotherapy in oral squamous cell carcinoma (OSCC). We used DNA microarray analysis to identify differences in gene expression after X-ray irradiation. We compared the gene expression profiles between X-ray (8 Gy)-irradiated Ca9-22 cells (an OSCC-derived cell line) and unirradiated Ca9-22 cells. A total of 167 genes with a 2-fold higher level of expression induced by X-ray irradiation were identified. Lipocalin-2 (LCN2) had the greatest increase in expression after X-ray irradiation, and it was categorized in a network that has cancer-related functions with the Ingenuity Pathway Analysis tool. Upregulated expression of LCN2 mRNA was validated by real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) analysis. When the LCN2 gene was knocked down in OSCC cells (Ca9-22 and HSC-2) and lung cancer cells (A549) by using small interfering RNA, the radiosensitivity of these cells was enhanced. Our findings suggest that the overexpression of LCN2 is likely associated with radioresistance in oral cancer and lung cancer cells, and that LCN2 expression levels could be used to predict radioresistance. Thus, regulating the expression or function of LCN2 could enhance the radiation response, resulting in a favorable outcome of radiotherapy.
View Figures
View References

Related Articles

Journal Cover

April 2013
Volume 42 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shiiba M, Saito K, Fushimi K, Ishigami T, Shinozuka K, Nakashima D, Kouzu Y, Koike H, Kasamatsu A, Sakamoto Y, Sakamoto Y, et al: Lipocalin-2 is associated with radioresistance in oral cancer and lung cancer cells. Int J Oncol 42: 1197-1204, 2013.
APA
Shiiba, M., Saito, K., Fushimi, K., Ishigami, T., Shinozuka, K., Nakashima, D. ... Tanzawa, H. (2013). Lipocalin-2 is associated with radioresistance in oral cancer and lung cancer cells. International Journal of Oncology, 42, 1197-1204. https://doi.org/10.3892/ijo.2013.1815
MLA
Shiiba, M., Saito, K., Fushimi, K., Ishigami, T., Shinozuka, K., Nakashima, D., Kouzu, Y., Koike, H., Kasamatsu, A., Sakamoto, Y., Ogawara, K., Uzawa, K., Takiguchi, Y., Tanzawa, H."Lipocalin-2 is associated with radioresistance in oral cancer and lung cancer cells". International Journal of Oncology 42.4 (2013): 1197-1204.
Chicago
Shiiba, M., Saito, K., Fushimi, K., Ishigami, T., Shinozuka, K., Nakashima, D., Kouzu, Y., Koike, H., Kasamatsu, A., Sakamoto, Y., Ogawara, K., Uzawa, K., Takiguchi, Y., Tanzawa, H."Lipocalin-2 is associated with radioresistance in oral cancer and lung cancer cells". International Journal of Oncology 42, no. 4 (2013): 1197-1204. https://doi.org/10.3892/ijo.2013.1815